Endonovo Therapeutics, Inc. (ENDV)
- Previous Close
0.0028 - Open
0.0027 - Bid --
- Ask --
- Day's Range
0.0026 - 0.0027 - 52 Week Range
0.0010 - 0.0200 - Volume
45,366 - Avg. Volume
1,242,931 - Market Cap (intraday)
835,130 - Beta (5Y Monthly) -0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
www.endonovo.comRecent News: ENDV
Performance Overview: ENDV
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENDV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENDV
Valuation Measures
Market Cap
835.13k
Enterprise Value
7.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.86
Price/Book (mrq)
--
Enterprise Value/Revenue
30.86
Enterprise Value/EBITDA
-3.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-144.27%
Return on Equity (ttm)
--
Revenue (ttm)
255.72k
Net Income Avi to Common (ttm)
-4.4M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
2.15M